A phase II study assessing CST-2032 for neurodegenerative disorders
Latest Information Update: 22 Sep 2020
At a glance
- Drugs CST-107 (Primary) ; CST-2032 (Primary)
- Indications Neurodegenerative disorders
- Focus Therapeutic Use
- Sponsors CuraSen Therapeutics
- 22 Sep 2020 New trial record
- 15 Sep 2020 According to a CuraSen Therapeutics media release, this study is anticipated to begin in 2021.